Abstract
BackgroundChimeric antigen receptor (CAR) T cell therapy has achieved encouraging results for patients suffering from B and plasma cell diseases. Clinical success in acute myeloid leukemia (AML) is however still...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
